title: Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse.
authors.affiliation: Department of Haematology, University College London Hospitals NHS Trust, London, UK.|Department of Haematology, UCL Cancer Institute, University College London, London, UK.
authors.forename: Yasmin
authors.initials: Y
authors.lastname: Reyal
authors.affiliation: Department of Haematology, University College London Hospitals NHS Trust, London, UK.|Department of Haematology, UCL Cancer Institute, University College London, London, UK.
authors.forename: Rakesh
authors.initials: R
authors.lastname: Popat
authors.affiliation: Department of Haematology, University College London Hospitals NHS Trust, London, UK.
authors.forename: Simon
authors.initials: S
authors.lastname: Cheesman
authors.affiliation: Department of Haematology, University College London Hospitals NHS Trust, London, UK.
authors.forename: Ali
authors.initials: A
authors.lastname: Rismani
authors.affiliation: Department of Haematology, University College London Hospitals NHS Trust, London, UK.
authors.forename: Shirley
authors.initials: S
authors.lastname: D'Sa
authors.affiliation: Department of Haematology, University College London Hospitals NHS Trust, London, UK.
authors.forename: Neil
authors.initials: N
authors.lastname: Rabin
authors.affiliation: Department of Haematology, University College London Hospitals NHS Trust, London, UK.|Department of Haematology, UCL Cancer Institute, University College London, London, UK.
authors.forename: Kwee
authors.initials: K
authors.lastname: Yong
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D012008:Recurrence; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000069286:Bortezomib
keywords: bortezomib; myeloma; myeloma therapy; relapse